Pharma industry spending on lobbying exploded in 2018

The trade group for the U.S.'s top drugmakers spent a record amount––$27.5 million––on lobbying efforts in 2018, according to Bloomberg.

The spending, which was disclosed by the Pharmaceutical Research and Manufacturers of America (PhRMA), was $1.4 million more than what was reported in 2009, when the Affordable Care Act was crafted. The association spent nearly $10 million during the first three months of 2018 to lobby Congress and the Trump administration—its biggest-ever quarter, Bloomberg reported. More than $6 million was spent on lobbying efforts in the fourth quarter of 2018.

The spending surge was a reaction to the potentially “most challenging year in decades” for the industry.

The lobbying disclosure comes at a time when rising drug prices have garnered negative attention from President Trump, lawmakers and consumers. For example, the cost of managing diabetes has increased significantly from 2012 to 2016, according to a recent report.

The Trump administration has ramped up efforts to lower drug prices, while House Democrats launched an investigation into rising prices.

See the full story below:  

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”